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Abstract
Alzheimer’s disease is a human brain disease that affects a significant fraction of the
population by causing problems with short-term memory, thinking, spatial orientation and
behavior, memory loss and other intellectual abilities. Up to date there is no singular test that
can definitively diagnose Alzheimer's disease, although imaging technology designed to
detect Alzheimer's plaques and tangles is rapidly becoming more powerful and precise. In this
paper we introduce a decision-making model, based on the combination of mitochondrial
hypothesis-dynamics with the role of electromagnetic influences of the metal ions into the
inner mitochondrial membrane and the quantitative analysis of mitochondrial population.
While there are few disappointing clinical-trial results for drug treatments in patients with
Alzheimer’s disease, scientific community need alternative diagnostic tools rather investing
mainly in amyloid-targeting drugs.
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1. Strategies for early diagnosis
There are few cases where scientists and pharmaceutical companies undergo trials in
cognitively normal individuals and patients with mild cognitive impairment (MCI)
combining already approved therapeutic agents with neuropsychological tests, blood
and urine analyses, quantitative magnetic resonance imaging (MRI) or magnetic
resonance spectroscopy (MRS), in order to evaluate the current hypotheses on the
etiology of AD. Additionally, there are several tests in the market for the early
diagnosis of MCI and AD, such as the 30-minute cognition test, which involves
recording of brainwaves while patient listen to auditory stimuli. In this 30-minute
cognition test for example, researchers found that AD patients process the sounds
differently than healthy adults. Additionally, we can refer to nuclear medicine
techniques that are established for diagnostic and research purposes such as Positron
Emission Tomography (PET) and CAT/CT and Nuclear Magnetic Resonance
Imaging (NMRI/ MRI), even though there are major limitations in terms of either cost
or image resolution, as well as patient irradiation or Fluorescence spectroscopic
techniques that are capable of single cell or molecule detection and imaging. These
novel techniques, combined with the capabilities of several Nanotechnological
techniques, such as μMRI and Scanning Tunneling Microscopy (STM), may offer the
early detection of AD in terms of modern biophysics. According to several studies,
neurodegenerative diseases are highly associated to mitochondrial disorders i.e. the
low production of ATP, decreased mitochondrial membrane potential and mutations
in mtDNA are factors related to disorders like AD.
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2In the brain, mitochondrial function declines with age and this functional decline
associates with increased mitochondrial biogenesis. In various neurodegenerative
disease states brain mitochondrial function declines even further, perhaps to the point
where mitochondrial biogenesis can no longer compensate for functional declines
(Swerdlow et al., 2004; Swerdlow et al., 2009; Onyango et al., 2010). While AD can
be genetically classified as familiar or sporadic, researchers proposed that beside the
main components of the plaques and tangles, amyloid-β (Αβ) and Tau proteins, the
case of sporadic AD is also a consequence of decreased mitochondrial function over
age. The overexpression of Αβ causes an alteration in the mitochondrial fission and
fusion proteins resulting in mitochondrial dysfunction, mitochondrial fragmentation,
increase in reactive oxygen species (ROS) and ATP production and reduced
mitochondrial membrane potential (Wang et al., 2008). Following a modern
biophysical explanation of abnormalities in the electron flow through the inner
mitochondrial membrane, defined as ‘electric thrombosis’ (Alexiou et al., 2011), we
examined whether these unusual interactions and electrical complexes are symptoms
and etiology of AD or just a consequence of the disease. In this paper we propose the
notion Mitochondrial Electrophysiology (ME) as a valuable novel method for use by
clinical investigators to study brain activity in patients with neurological illness.
While the role of several metal ions is already known, Copper, Zinc and Iron
metabolisms seem to play fundamental role in the mitochondrial dynamics and the
quality of mitochondrial population. Therefore, the proposed procedure combines
peripheral electrophysiology measurements with identification of electromagnetic
interaction in subcellular level and offers a comprehensive statistical evaluation of
these factors and AD progress. Our decision-making model, named AVAD, concerns
physical and cellular-subcellular evaluation such as reported medical history and
nutritionals habits, quantitative analysis and distribution of mitochondrial dynamics,
electrophysiology measurements, mtDNA analysis and metal ions metabolism.
2. Mitochondrial dynamics and amyloid-β interaction
Recent studies have shown that mitochondria are significantly reduced in AD,
supporting a topographic and probably temporal relationship between neuronal
oxidative damage and mitochondrial abnormalities (Hirai et al., 2001). Although the
pathological mechanism for AD is still unknown, the predominant hypothesis is that
excess Aβ production results in cellular toxicity. Transgenic mouse models over-
expressing amyloid precursor protein (APP) lead to amyloid plaques associated with
activation of inflammatory cells, localized loss of neurons, and some cognitive
behavioral changes (Dodart et al., 2005). Ab can localize to mitochondria, and this
interaction has been suggested to underlie in part their cytotoxic effects (Manczak et
al., 2006; Lustbader et al., 2004).
2.1 The mitochondrial hypothesis in AD
The mechanisms that cause the profound degeneration and loss of neurons in AD are
not known, and existing information is incomplete. Abnormal processing or
modification of APP and the cytoskeletal protein tau are involved in the pathogenesis
resulting in amyloid (Aβ) deposits and neurofibrillary changes consisting of paired
helical filaments, NFTs and dystrophic neurites (Hardy et al., 2002).
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combination of several mechanisms including perturbations in protein metabolism,
excitotoxicity, oxidative stress, mitochondrial perturbations, and inflammation. The
possible specific mechanisms for neuronal degeneration in AD may involve
dysfunction of NMDA receptors (Sze et al., 2001; Kemp et al., 2002), deregulation of
Ca2+ and mitochondrial homeostasis (Mattson et al., 1993; Reddy et al., 2008), defects
in synapses (DeKosky et al., 1990; Terry et al., 1991; Martin et al., 1994; Sze et al.,
1997; Selkoe, 2002), abnormalities in the metabolism of APP and presenilin proteins,
toxic actions of Aβ protein derived from APP (Yankner et al., 1989; Younkin, 1995),
and cytoskeletal pathology (Fath et al., 2002; Rapoport et al., 2002). There are
possible disease links between intraneuronal Aβ and mitochondria suggesting an
intracellular toxicity of Aβ (Anandatheerthavarada et al., 2003; Devi et al., 2006;
Manczak et al., 2006). Human AD autopsy brain shows evidence for mitochondrial
impairments (Reddy et al., 2008). High mitochondrial APP levels mirror
abnormalities in respiratory chain subunit levels and activity and enhanced ROS
production (Devi et al., 2006). Aβ can interact with the mitochondrial matrix protein
Aβ-binding alcohol dehydrogenase in human AD brain and is believed to participate
in mitochondrial dysfunction and oxidative stress (Lustbader et al., 2004), while
increased production of Aβ may be a consequence of neuronal apoptosis.
Additionally, defects in mitochondrial dynamics, fusion and fission have been shown
to decrease mitochondrial movement. Empirically, fusion-deficient mitochondria
display loss of directed movement, following Brownian motion without exact
formulation of movement properties (Chen et al., 2003). In neurons lacking
mitochondrial fusion, both increased mitochondrial diameter due to swelling and
aggregations of mitochondria seem to block efficient entry into neurites, resulting in a
death of mitochondria in axons and dendrites (Chen et al., 2007). These defects result
in improperly developed neurons or gradual neurodegeneration. It is obvious that
neurodegeneration that occurs in AD has not been cleared identified and even more
many risk factors such as aging, increased oxidative stress, inflammatory processes,
mitochondrial dysfunction, alterations in mitochondrial morphology and even cell
cycle abnormalities have been proposed as components of AD pathogenesis.
2.2 Amyloid-β interacting metal ions. The case of imaging diagnosis
Metal ions are known to play an important role in many neurodegenerative diseases
beside AD including, aceruloplasminemia, amyotrophic lateral sclerosis, Huntington
disease, Menkes disease, occipital horn syndrome, Parkinson disease, prion disease,
Wilson disease etc. In these diseases improper regulation of redox active metal ions
can induce oxidative stress by producing cytotoxic ROS. For example, Copper
binding proteins play important roles in the establishment and maintenance of metal-
ion homeostasis, in deficiency disorders with neurological symptoms like Menkes
disease and Wilson disease and in neurodegenerative diseases like AD. The
interaction of Fe and Cu with Aβ may lead to production of H2O2 due to double
electron transfer to O2 (Bush, 2008) resulting in differentiations from the normal
measurements. The production of H2O2 is known to be partly responsible for
oxidative injury in cases of AD (Nazem et al., 2011). Furthermore, the interaction of
Aβ with cell membrane is enhanced by Zn and Cu (Cui et al., 2005) and Cu could
play an important role in the neurotoxicity of Aβ (Huang et al., 1999).
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the role of metals in neurodegenerative disorders in general. Imaging techniques like
X-ray fluorescence microscopy (XFM), particle induced X-ray emission (PIXE),
energy dispersive X-ray spectroscopy (EDS), laser ablation inductively coupled mass
spectrometry (LA-ICP-MS), secondary ion mass spectrometry (SIMS) or magnetic
resonance imaging (MRI) are widely researched for the imaging of metals in intact
biological cells and tissues with high spatial resolution and detection sensitivity
(Skaat et al., 2009; Hofmann-Amtenbrink et al., 2010; Nazem et al., 2011). However,
these techniques are mostly useful for AD verification rather than early diagnosis
since the amyloid plaques formation appears in a later stages.
3. The AVAD decision-making model
The proposed novel procedure for early identification of AD aims at combining
bioinformatics methods with imaging techniques and electrophysiology
measurements with associated known mitochondrial markers in order to identify
symptomatology of AD in early stages. The AVAD model consists of the statistical
evaluation of the four different clinical assessments below, associated with the
mitochondrial hypothesis and their identified correlation with progressive AD.
3.1 Evaluation of mitochondrial population as a dynamic system
We established a new dynamic mathematical model for the association of alterations
in mitochondrial distribution and morphology due to imbalance motility. This new
stochastic model replaces the general hypothesis of Brownian motion and enables a
more accurate detection of movement’s dysfunction as it has been cleared identified
in our simulation process. While the motility plays an important role on fission and
fusion, in the case of decreased functionality creates clusters of mitochondria or even
more isolated individual mitochondria as this was demonstrated in cases of skin
biopsies.
3.2 Electromagnetic interactions in the mitochondrial population
It is cleared form the simulation results and the microscopy testing, that there is a
great impact form the reflection of decreased mitochondrial motility on ΔΨ of inner
membrane. The pathogenesis on inner membrane potential had been investigated
through a total new experimental approach on the way that metal ions Cu and Fe
interact to each other and with oxygen and amyloid-β peptide (Aβ) as well, in the
specific biological environment. This study is an extension of the initial formulation
of the electric complexes that occurs due to the phenomenon of ‘electric thrombosis’
in regards to certain Tc (temperature) and pH levels, in order to identify the existence
of H2O2 (hydrogen peroxide) or OH* (hydroxyl radical).
3.3 Metal ions metabolim and mtDNA analysis
A detailed statistical analysis took place in order to identify all the correlations
between Copper metabolisms, cytotoxic effects of Zn and existence of heavy metals
in combination with clinical assessment for early diagnosis of MCI.
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account as well as weight maintenance and physical activity. Additionally increased
levels of mtDNA mutations and alterations in complex IV subunits analysis were also
evaluated in patients.
3.4 Frequencies and electromagnetic analysis
EEG frequencies, bio potential measurements and electromagnetic influences were
taken also in consideration; monitoring cases of decreased ‘natural superconduction’
of inner membrane and reduction of ATP in the mitochondrial population using AFM,
were statistical evaluated, as evidences for MCI cases.
3.5 Clinical Study
We used clinical assessments of an 86 control asymptomatic population in order to
test a sample of 45 MCI subjects and a sample of 25 mild to moderate AD patients.
The subjects were for 60 to 85 years old. The groups were also compared and
evaluated in terms of demographic, history health, cardiovascular risk factors, chronic
diseases and identification of genetic disorders mainly of copper metabolism leading
to severe copper toxicity. Copper is known to interact with amyloid precursor protein
and β-amyloid peptide in the self-aggregating plaques and neurofibrillary tangles
characteristic of AD and may contribute to the pathogenesis of this disorder via
cellular oxidative stress (Madsen et al., 2007; Zucconi et al., 2007; Lutsenko et al.,
2007; Taylor et al., 2002; Dingwall, 2007; Ha et al., 2007). Brain normally contains a
certain trace concentration of metal ions like Zinc, Copper and Iron, which possess
different physiological roles (Bush, 2008). Any disruption in the homeostasis of these
trace elements leading to higher concentrations of these ions may impose several
proteins and membrane lipids to toxic effects of these trace elements and finally end
in production of ROS (Bush, 2008; Castellani et al., 2007; Smith, 2006; Huang et al.,
2004). Skin biopsies results were used for immunochemistry and electron
micrographs on Schwann cells and dermal nerves and were evaluated using
multinomial regression analysis. EEG measurements and skin bio potentials were also
evaluated using Fisher’s exact test and Chi-square test. AFM was used in order to
confirm measurements on the natural superconductivity on inner mitochondrial
membrane and evaluate surface structures in the cases of mitochondria interaction and
inner membrane potential distribution. Mitochondria size and count were also
evaluated and measured and the statistical significance to the control group was
assessed using Student's t-test. In the overall case, the sensitivity and specificity of the
protocol according to the specific combined clinical assessments was calculated on
95.6%, a secure rate for the early identification of mild AD symptoms.
4. Future applications
In our case in question, we evaluated bio potential measurements in combination with
AFM study and EEG frequencies, in order to identify mitochondrial dysfunction and
statistical evaluate a novel decision-making model in targeted sample population,
concerning MCI and early stages of AD.
The modern biophysics seems to offer powerful tools that are not yet been applied in
bioengineering and molecular biology. This novel model is innovative and accurate
6but mostly has a low cost against imaging techniques and can be designed in the
future for individualized diagnosis as a mobile device. Latest news from the drug
developers’ clinical trials in AD patients is quite pessimistic in order to prove amyloid
hypothesis as a diagnostic symptom and effective treatment (Callaway, 2012).
Nevertheless the exclusively targeting of amyloid-β, alongside the tardiness disease
progression and drug application are disappointing indicating an ineffective strategy.
This new hybrid decision-making model combines bioengineering with modern
biophysics. Definitely we do not propose a drug treatment but a more sophisticated
complex tool for evidence’s assessment on identification of AD.
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